
Sanofi to acquire Inhibrx for approximately $1.7bn
Betsy Goodfellow | January 23, 2024 | News story | Business Services | Inhibrx, Rare Diseases, Sanofi, acquisition
Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following the spin-off of non-INBRX-101 assets into New Inhibrx.
INBRX-101 is a human recombinant protein for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD), allowing them to achieve normalisation of serum AAT levels with less frequent dosing.
The protein has already successfully completed a phase 1 trial, in which it demonstrated positive safety and pharmacokinetics results. Enrolment for the phase 2 trial is currently underway.
Under terms of the agreement, Sanofi will pay $30 per share, equaling an approximate total value of $1.7bn, as well as further milestone payments. New Inhibrx will retain non-INBRX-101 assets such as its immune-oncology pipeline, however Sanofi will gain an 8% equity stake in New Inhibrx.
Houman Ashrafian, head of research and development at Sanofi, commented: “The addition of INBRX-101 as a high potential asset to our rare disease portfolio reinforces our strategy to commit to differentiated and potential best-in-class products. With our expertise in rare diseases and growing presence in immune-mediated respiratory conditions, INBRX-101 will complement our approach to deploy R&D efforts in key areas of focus and address the needs of the underserved AATD patients and communities.”
Betsy Goodfellow
Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …






